Affordable Access

deepdyve-link deepdyve-link
Publisher Website

New class of agents for treatment of hypertension: focus on direct renin inhibition.

Authors
Type
Published Article
Journal
Vascular Health and Risk Management
1178-2048
Publisher
Dove Medical Press
Publication Date
Volume
6
Pages
869–882
Identifiers
DOI: 10.2147/VHRM.S4189
PMID: 20957132
Source
Medline
Keywords
License
Unknown

Abstract

Aliskiren, the first orally active direct renin inhibitor, is an effective antihypertensive drug with distinctive characteristics, including good blockade of the renin-angiotensin system, a prolonged duration of action, pharmacologic effects that persist after drug discontinuation, and favorable tolerability comparable with placebo. The blood pressure-lowering effect of aliskiren monotherapy is similar, if not superior, to that of other first-line antihypertensive agents, and is greatly enhanced when aliskiren is combined with various other antihypertensive medications, without any adverse drug interactions. Aliskiren is also an effective and well tolerated therapy in special populations, including diabetic, obese, and elderly hypertensives. Beyond its blood pressure-lowering efficacy, results from experimental and clinical trials suggest that aliskiren has positive effects on markers of cardiovascular and renal damage. The ASPIRE (Aliskiren Study in Post-MI patients to Reduce rEmodelling) HIGHER clinical trials program is further assessing whether the promising pharmacologic properties of aliskiren translate into reduced risk of adverse cardiovascular and renal outcomes.

Statistics

Seen <100 times